Curis (NASDAQ: CRIS) regains Nasdaq compliance but faces strict one-year review

Rhea-AI Filing Summary

Curis, Inc. reports that it has regained compliance with Nasdaq Listing Rule 5550(b)(2), meaning its common stock currently meets Nasdaq’s minimum market value of listed securities requirement and the terms set by a Nasdaq Hearings Panel.

Under Nasdaq Listing Rule 5815(d)(4)(A), Curis will remain under a one-year discretionary Panel monitoring period. If it falls out of compliance with any Nasdaq listing rule during this time, it will not receive a cure period or extra time to fix the issue. Instead, Nasdaq staff would issue a delisting determination, after which Curis could request a new hearing, and its securities may ultimately be delisted from Nasdaq.

Insights

Equity Listing & Market Structure Analyst

Curis regains Nasdaq compliance but faces strict one-year monitoring.

Curis, Inc. has regained compliance with Nasdaq Listing Rule 5550(b)(2), restoring full adherence to the listing standards set by a Nasdaq Hearings Panel. This keeps its common stock trading on the Nasdaq Capital Market, avoiding immediate delisting risk.

However, Nasdaq has imposed a one-year Discretionary Panel Monitor under Listing Rule 5815(d)(4)(A). During this period, any new deficiency in any Nasdaq listing rule would trigger an automatic delisting determination without the usual opportunity to submit a compliance plan or receive a cure period.

If a new deficiency occurs, Nasdaq staff would issue a Delist Determination Letter, and Curis could request a hearing before the same or a newly convened Hearings Panel. That Panel could still decide that the company’s securities be delisted, so ongoing adherence to all listing requirements remains critical.

0001108205false00011082052026-02-032026-02-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

_____________________

FORM 8-K

_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): February 3, 2026

Curis, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware			000-30347			04-3505116
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(I.R.S. Employer Identification Number)

128 Spring Street, Building C - Suite 500, Lexington, MA 02421

(Address of Principal Executive Offices) (Zip Code)

(617) 503-6500

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
			☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:        

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, Par Value $0.01 per share

CRIS

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On February 3, 2026, Curis, Inc. (the “Company”) received written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(2) (“MVLS Rule”) and is in full compliance with the terms set forth by the Nasdaq Hearings Panel (the “Panel”).

Pursuant to Listing Rule 5815(d)(4)(A), the Company will be subject to a Discretionary Panel Monitor for a period of one-year. If, within the one-year monitoring period, the Listing Qualifications Department (“Staff”) finds the Company again out of compliance with any of Nasdaq’s Listing Rules, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, the Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. The Company will have the opportunity to respond/present to the Hearings Panel as provided by Listing Rule 5815(d)(4)(C). The Company’s securities may be at that time delisted from Nasdaq.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, any statements with respect Company’s ability to maintain its listing on Nasdaq or to request any future hearings with any Hearings Panel. Forward-looking statements may contain the words "believes," "expects," "anticipates," "plans," "intends," "seeks," "estimates," "assumes," "predicts," "projects," "targets," "will," "may," "would," "could," "should," "continue," "potential," "focus," "strategy," "mission," or similar expressions. Actual results may differ materially from those indicated by such forward-looking statements. “Risk Factors” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and in other filings that the Company periodically makes with the SEC. In addition, any forward-looking statements represent the views of the Company only as of today and should not be relied upon as representing the Company’s views as of any subsequent date. The Company disclaims any intention or obligation to update any of the forward-looking statements after the date of this Current Report on Form 8-K whether as a result of new information, future events or otherwise, except as may be required by law.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Curis, Inc.
Date:			February 9, 2026			By:			/s/ Diantha Duvall
									Diantha Duvall
									Chief Financial Officer

FAQ

What did Curis, Inc. (CRIS) announce regarding its Nasdaq listing status?

Curis announced it has regained compliance with Nasdaq Listing Rule 5550(b)(2), which governs the market value of listed securities. This means its common stock currently meets Nasdaq’s continued listing standards set by a prior Hearings Panel decision.

What is the one-year Nasdaq Discretionary Panel Monitor for Curis (CRIS)?

Nasdaq placed Curis under a one-year Discretionary Panel Monitor under Listing Rule 5815(d)(4)(A). During this period, any new listing deficiency triggers stricter consequences, including an automatic delisting determination without the usual cure or compliance period.

What happens if Curis, Inc. (CRIS) becomes non-compliant with Nasdaq rules during the monitoring period?

If Curis falls out of compliance with any Nasdaq listing rule within the one-year monitoring period, Nasdaq staff will issue a Delist Determination Letter. Curis will not be allowed to submit a compliance plan or receive extra time before that determination.

Can Curis (CRIS) appeal a Nasdaq delisting determination during the monitoring period?

Yes. If Nasdaq issues a Delist Determination Letter, Curis may request a new hearing under Listing Rule 5815(d)(4)(C). The hearing would be before the original Hearings Panel, if available, or a newly convened Panel to review the determination.

Could Curis, Inc. (CRIS) be delisted from Nasdaq despite regaining compliance?

Yes. Although Curis has regained compliance, its securities may still be delisted if it again fails any Nasdaq listing rule during the one-year monitoring period and the Hearings Panel ultimately upholds a delisting determination after a requested hearing.

What forward-looking risks does Curis (CRIS) highlight about its Nasdaq listing?

Curis includes forward-looking statements about its ability to maintain its Nasdaq listing and request future hearings. It cautions that actual results may differ materially, referencing risk factors in its Annual Report on Form 10-K and other SEC filings.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.9 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 13.3 KB